PRGO:NYSEPerrigo Company plc Analysis
Data as of 2026-06-17 - not real-time
$10.67
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Perrigo is trading well below its short‑term and medium‑term moving averages, and the MACD has turned bearish, suggesting continued downside pressure in the near term. The RSI sits in a neutral zone, while price is hovering just above a key support level and well beneath the nearest resistance, framing a tight trading range. Volatility is markedly elevated and beta indicates the stock moves more aggressively than the broader market, amplifying risk for short‑duration holders. The dividend yield is exceptionally high, but the payout ratio exceeds earnings, raising serious concerns about the sustainability of the payout. Financially, the company carries a heavy debt load relative to equity and has posted a negative profit margin, though forward earnings estimates have turned positive and analysts project a sizable upside. Mixed recent news shows the stock alternating between outperformance and underperformance, underscoring the uncertainty surrounding its short‑term trajectory.
Despite the challenges, valuation multiples are dramatically lower than industry peers, with price‑to‑earnings and price‑to‑book ratios indicating that the stock is deeply discounted. Analyst price targets imply a substantial upside potential, and the forward earnings outlook offers a glimpse of a possible earnings turnaround. The combination of a low valuation, high dividend yield (albeit risky), and a favorable earnings outlook makes the stock attractive for investors with a longer horizon who can tolerate the current volatility and leverage concerns.
Despite the challenges, valuation multiples are dramatically lower than industry peers, with price‑to‑earnings and price‑to‑book ratios indicating that the stock is deeply discounted. Analyst price targets imply a substantial upside potential, and the forward earnings outlook offers a glimpse of a possible earnings turnaround. The combination of a low valuation, high dividend yield (albeit risky), and a favorable earnings outlook makes the stock attractive for investors with a longer horizon who can tolerate the current volatility and leverage concerns.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish technical indicators and price below key moving averages
- Elevated volatility and higher‑than‑average beta
- Unsustainable dividend payout ratio
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant upside implied by analyst price targets
- Deep discount to industry valuation multiples
- Forward earnings estimate turning positive
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Potential earnings recovery and cash flow improvement
- High dividend yield as a supplemental return if sustainability improves
- Strategic position in the OTC self‑care market despite competitive pressures
Key Metrics & Analysis
Financial Health
Revenue Growth-7.20%
Profit Margin-43.50%
P/E Ratio4.5
ROE-52.23%
ROA2.09%
Debt/Equity153.22
P/B Ratio0.5
Op. Cash Flow$189.4M
Free Cash Flow$108.4M
Industry P/E24.7
Technical Analysis
TrendBearish
RSI44.7
Support$10.19
Resistance$11.95
MA 20$10.96
MA 50$11.21
MA 200$14.67
MACDBearish
VolumeIncreasing
Fear & Greed Index92.13
Valuation
Target Price$16.50
Upside/Downside54.64%
GradeUndervalued
TypeBlend
Dividend Yield10.84%
Risk Assessment
Beta1.09
Volatility47.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.